UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer

Guan,Ge Ge; Wang,Wen Bo; Lei,Bing Xin; Wang,Qiao Li; Wu,Lin; Fu,Zhen Ming; Zhou,Fu Xiang; Zhou,Yun Feng

doi:10.3892/ol.2015.2926

UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in esophageal cancer

Authors:
- Ge Ge Guan
- Wen Bo Wang
- Bing Xin Lei
- Qiao Li Wang
- Lin Wu
- Zhen Ming Fu
- Fu Xiang Zhou
- Yun Feng Zhou
View Affiliations

Affiliations: Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: February 3, 2015 https://doi.org/10.3892/ol.2015.2926
Pages: 1567-1574
Copyright: © Guan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human telomerase reverse transcriptase (hTERT) is a critical factor in unlimited cell proliferation and immortalization, with numerous studies demonstrating that high expression of hTERT is a poor prognostic factor in various types of cancer. Ubiquitin‑conjugating enzyme E2D 3 (UBE2D3) is a member of the E2 family, and participates in the ubiquitin proteasome pathway to regulate basic cellular activities, such as cell cycle control, the DNA damage response, apoptosis, and tumorigenesis. Our previous study initially determined that downregulation of UBE2D3 expression increases hTERT expression and cell proliferation, however, the association between the expression of these two proteins and their functions in cancer tissues remains unknown. Therefore, the protein expression levels of hTERT and UBE2D3 were evaluated in 150 esophageal cancer and 30 adjacent healthy tissue samples by performing immunohistochemical analysis. Concurrently, the clinicopathological data of the enrolled patients were obtained to allow correlation analysis. It was identified that the expression of hTERT in the esophageal cancer tissues was significantly higher compared with that of the adjacent tissues (P=0.015), however, the expression of UBE2D3 was significantly lower in esophageal cancer tissues than the adjacent tissues (P=0.001). Additionally, the study demonstrated that hTERT was significantly upregulated in poorly‑differentiated, advanced tumor‑node‑metastasis (TNM) stage cancer tissues (P<0.05 for all), however, UBE2D3 expression was downregulated in poorly‑differentiated, lymph node invaded cancer tissues and recurrent cases. It was also identified that traditional factors, including tumor location, T stage, lymph node status, TNM stage, and molecular factors of hTERT and UBE2D3, were significantly associated with overall survival time (P<0.05 for all). Furthermore, UBE2D3, lymph node status and tumor location were independent prognostic factors for esophageal cancer in multivariate analysis. Most notably, hTERT and UBE2D3 expression were negatively correlated with each other. In conclusion, the findings of the present study indicated that hTERT and UBE2D3 proteins appear to be involved in the development of esophageal cancer, that UBE2D3 may a positive prognostic factor for esophageal cancer, and that UBE2D3 and hTERT expression levels are inversely correlated.

View Figures

View References

1	Yang H and Chen YX: Improvement analysis of article quality in World Journal of Gastroenterology during 2008–2012. World J Gastroenterol. 19:7830–7835. 2013. View Article : Google Scholar : PubMed/NCBI
2	Mao WM, Zheng WH and Ling ZQ: Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 12:2461–2466. 2011.
3	Wang X, Fan JC, Wang AR, et al: Epidemiology of esophageal cancer in Yanting - regional report of a national screening programme in China. Asian Pac J Cancer Prev. 14:2429–2432. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lin Y, Totsuka Y, He Y, et al: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
6	Gertler R, Stein HJ, Langer R, et al: Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 253:689–698. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lu W, Zhang Y, Liu D, et al: Telomeres - structure, function, and regulation. Exp Cell Res. 319:133–141. 2013. View Article : Google Scholar
8	Philippi C, Loretz B, Schaefer UF and Lehr CM: Telomerase as an emerging target to fight cancer - opportunities and challenges for nanomedicine. J Control Release. 146:228–240. 2010. View Article : Google Scholar : PubMed/NCBI
9	Counter CM, Meyerson M, Eaton EN, et al: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 16:1217–1222. 1998. View Article : Google Scholar : PubMed/NCBI
10	Ulaner GA, Hu JF, Vu TH, et al: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58:4168–4172. 1998.PubMed/NCBI
11	Proctor A, Brownhill SC and Burchill SA: The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility. Biochim Biophys Acta. 1792:260–274. 2009. View Article : Google Scholar : PubMed/NCBI
12	Simsek BC, Pehlivan S and Karaoglu A: Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features. Ann Diagn Pathol. 14:413–417. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wang G, Wang W, Zhou J and Yang X: Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer. Cancer Biomark. 13:21–28. 2013.PubMed/NCBI
14	Poremba C, Heine B, Diallo R, et al: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 198:181–189. 2002. View Article : Google Scholar : PubMed/NCBI
15	Tu Y, Chen C, Pan J, et al: The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 5:726–738. 2012.PubMed/NCBI
16	Amm I, Sommer T and Wolf DH: Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochim Biophys Acta. 1843:182–196. 2014. View Article : Google Scholar
17	Clague MJ and Urbé S: Ubiquitin: same molecule, different degradation pathways. Cell. 143:682–685. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kleiger G and Mayor T: Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. 24:352–359. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wang W, Yang L, Hu L, et al: Inhibition of UBE2D3 expression attenuates radiosensitivity of MCF-7 human breast cancer cells by increasing hTERT expression and activity. PLoS One. 8:e646602013. View Article : Google Scholar : PubMed/NCBI
20	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 7th edition. Wiley-Blackwell; sWest Sussex: 2009
21	Yang CH, Hung WC, Wang SL, et al: Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma. APMIS. 116:309–316. 2008. View Article : Google Scholar : PubMed/NCBI
22	Fujita T, Ikeda H, Kawasaki K, et al: Clinicopathological relevance of UbcH10 in breast cancer. Cancer Sci. 100:238–248. 2009. View Article : Google Scholar
23	Kumaki F, Kawai T, Hiroi S, et al: Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol. 32:188–195. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yam PC, Tong D and Law S: Comparisons of sixth and seventh edition of the American Joint Cancer Committee staging systems for esophageal cancer. Ann Surg Oncol. 21:583–588. 2014. View Article : Google Scholar
25	Hsu PK, Wu YC, Chou TY, et al: Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 89:1024–1031. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hong JC, Murphy JD, Wang SJ, et al: Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis. Ann Surg Oncol. 20:3999–4007. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yang HX, Hou X, Liu QW, et al: Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Thorac Surg. 93:1861–1866. 2012. View Article : Google Scholar : PubMed/NCBI
28	Marjanovic G, Schricker M, Walch A, et al: Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer. J Gastrointest Surg. 15:29–37. 2011. View Article : Google Scholar
29	Dhupar R, Correa AM, Ajani J, et al: Concordance of studies for nodal staging is prognostic for worse survival in esophageal cancer. Dis Esophagus. 27:770–776. 2013. View Article : Google Scholar : PubMed/NCBI
30	Vallböhmer D, Brabender J, Metzger R and Hölscher AH: Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg. 14(Suppl 1): S75–S80. 2010. View Article : Google Scholar
31	Cheung PY, Deng W, Man C, et al: Genetic alterations in a telomerase-immortalized human esophageal epithelial cell line: Implications for carcinogenesis. Cancer Lett. 293:41–51. 2010. View Article : Google Scholar : PubMed/NCBI
32	Okawa T, Michaylira CZ, Kalabis J, et al: The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 21:2788–2803. 2007. View Article : Google Scholar : PubMed/NCBI
33	Sakabe R, Murakami Y, Uemura K, et al: Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma. Ann Surg Oncol. 19:3072–3080. 2012. View Article : Google Scholar : PubMed/NCBI
34	Page RC, Pruneda JN, Amick J, et al: Structural insights into the conformation and oligomerization of E2~ubiquitin conjugates. Biochemistry. 51:4175–4187. 2012. View Article : Google Scholar : PubMed/NCBI
35	Ye Y and Rape M: Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 10:755–764. 2009. View Article : Google Scholar : PubMed/NCBI
36	Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 29(Suppl 1): 3–9. 2003. View Article : Google Scholar : PubMed/NCBI
37	Khanna-Gupta A and Berliner N: ATRA: Finding targeted APL therapy targets. Blood. 110:476–477. 2007. View Article : Google Scholar
38	Mittal MK, Singh K, Misra S and Chaudhuri G: SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination. J Biol Chem. 286:469–479. 2011. View Article : Google Scholar :